Intech Investment Management LLC Acquires Shares of 15,797 Twist Bioscience Co. (NASDAQ:TWST)

Intech Investment Management LLC acquired a new position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 15,797 shares of the company's stock, valued at approximately $714,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of TWST. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. EdgeRock Capital LLC bought a new position in Twist Bioscience in the 2nd quarter worth approximately $43,000. Blue Trust Inc. grew its holdings in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company's stock valued at $58,000 after buying an additional 1,136 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience during the second quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Twist Bioscience by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after acquiring an additional 381 shares during the last quarter.

Analysts Set New Price Targets

TWST has been the topic of a number of research reports. Barclays reduced their price target on shares of Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a report on Tuesday, November 19th. Scotiabank boosted their target price on Twist Bioscience from $50.00 to $54.00 and gave the stock a "sector outperform" rating in a research report on Tuesday, November 19th. Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a report on Thursday, October 17th. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a report on Tuesday, October 1st. Finally, Robert W. Baird boosted their price target on shares of Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $51.00.

Twist Bioscience Stock Performance

TWST stock traded up $0.86 during mid-day trading on Friday, reaching $49.18. 508,411 shares of the stock traded hands, compared to its average volume of 948,382. The business has a 50-day moving average price of $43.84 and a two-hundred day moving average price of $46.25. Twist Bioscience Co. has a one year low of $23.25 and a one year high of $60.90. The stock has a market capitalization of $2.92 billion, a PE ratio of -13.66 and a beta of 1.78.

Insider Buying and Selling at Twist Bioscience

In other news, CAO Robert F. Werner sold 1,448 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $64,580.80. Following the sale, the chief accounting officer now owns 45,620 shares of the company's stock, valued at $2,034,652. This trade represents a 3.08 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, SVP Paula Green sold 1,057 shares of the firm's stock in a transaction on Monday, November 4th. The shares were sold at an average price of $41.56, for a total transaction of $43,928.92. Following the sale, the senior vice president now owns 121,013 shares in the company, valued at approximately $5,029,300.28. This represents a 0.87 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 98,118 shares of company stock valued at $4,391,151. 3.92% of the stock is owned by insiders.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.